Skip to main content
Toggle navigation
Search
Home
Cellular and T cell engager Immunotherapy
Home
Cellular and T cell engager Immunotherapy
Cellular and T cell engager Immunotherapy
Type here to filter the list
(PA-001) BCMA-Directed CAR-NK and BiKE Therapies Enhance NK Cell Cytotoxicity in Primary Multiple Myeloma
(PA-002) Safety and Efficacy of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Study
(PA-003) Real-World Comparison of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: A Center for International Blood & Marrow Transplantation Research (CIBMTR) Study
(PA-004) Real-world Bispecific Antibody Therapy for Multiple Myeloma: Insights from Dutch Nationwide Registry
(PA-005) The Role of Trogocytosis in BCMA CAR T Cell Therapy with Gamma-Secretase Inhbition
(PA-006) Comparative Effectiveness of Teclistamab vs Real-world Physician’s Choice of Carfilzomib-and/or Pomalidomide-based Regimens in Locommotion and Momment in TCE RRMM
(PA-007) Talquetamab Dosing Strategies in the United States: Real-world Insights from over 250 Patients
(PA-008) Economic Value of Tocilizumab Prophylaxis to Prevent Cytokine Release Syndrome (CRS) During Outpatient Teclistamab (Tec) or Talquetamab (Tal) Initiation for Relapsed/refractory Multiple Myeloma (RRMM)
(PA-009) Acquired FCRL5 Mutation Leading to Cevostamab Resistance in Multiple Myeloma
(PA-010) Efficacy/safety of Cilta-cel ± Lenalidomide Maintenance in Patients with Multiple Myeloma Who Had Suboptimal Response to Frontline ASCT: Updated Follow-up from CARTITUDE-2 Cohort D
(PA-011) Absolute Lymphocyte Count as a Key Biomarker for Monitoring Safety After Ciltacabtagene Autoleucel
(PA-012) Clonal Hematopoiesis of Indeterminate Potential (CHIP) Does Not Impact the Efficacy of BCMA Directed Chimeric Antigen Receptor (CAR)-T Cells in Patients with Relapsed/refractory Multiple Myeloma
(PA-013) Synergistic Anti-tumor Effects of CAR T Cells and a Personalized Tumor Vaccine
(PA-014) Outpatient Step-up Dosing of Teclistamab (TEC): An Implementation Process Shifting from the Academic Inpatient (IP) to Community Outpatient (OP) Setting
(PA-015) Non-linear Impact of BMI on Anti-bcma CAR-T Outcomes: Overweight Paradox in Myeloma
(PA-016) Delayed Hematologic Recovery After BCMA CAR-T Is Associated with Progressive Loss of Endogenous T Cell Diversity After CAR-T Infusion
(PA-017) Bispecific Outpatient Step-up Dosing with Prophylactic Dexamethasone: The BOSS Program Experience in Myeloma
(PA-018) Severe Tumor Flare Pain Syndrome During Step-Up Dosing of Teclistamab in High-Risk Relapsed/Refractory Multiple Myeloma
(PA-019) Factors Associated with Response, Neurotoxicity, and Survival in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell (CAR-T) Therapy
(PA-020) Real-world Outcomes Among Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Initiating Teclistamab (Tec) at a Large Community Oncology Center in the US
(PA-022) Real-World Long-Term Effectiveness and Safety Outcomes Among Patients Receiving Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
(PA-023) Outcomes of Teclistamab (Tec) Step-up Dosing in Outpatient/hybrid Settings Among a Large Sample of Relapsed Refractory Multiple Myeloma (RRMM) Patients Treated with Tec
(PA-024) Teclistamab and Talquetamab in Relapse/Refractory Multiple Myeloma (RRMM) Patients with Severe Renal Insufficiency: Case Series
(PA-025) Monitoring and Management of CMV and Other Viral Reactivations with Bispecific Antibodies (BsAbs) for Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
(PA-026) Evaluation of Sequential Absolute Lymphocyte Count (ALC) in Patients with Relapsed Multiple Myeloma (RRMM) with Cranial Nerve Palsies (CNPs) Post Ciltacabtagene-autoleucel (cilta-cel)
(PA-027) Linvoseltamab (LINVO) Monotherapy in Patients (pts) with Newly Diagnosed (ND) Multiple Myeloma (MM): Initial Dose-escalation Results from the Window of Opportunity LINKER-MM4 Trial
(PA-028) Development of anti-AL amyloidosis CAR Phagocyte Therapy
(PA-029) Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma
(PA-030) Health Care Contact Days After Standard of Care (SOC) B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR T) for Relapsed/Refractory Multiple Myeloma (RRMM).
(PA-031) Safety, Efficacy and Health After Teclistamab (SEHAT Study) in Patients with Relapsed and Refractory Multiple Myeloma; A Multicentric Real World Indian Experience
(PA-032) Immune Correlates of Response to T-Cell Engaging Bispecific Antibody Treatments in Multiple Myeloma
(PA-033) Reshaping Treatments: Insights from the BiTAL Study on Talquetamab in Relapsed Refractory Multiple Myeloma.
(PA-034) One-time ex-vivo Conditioning of CAR-T Cells with a Novel Metabolic Modulator
(PA-035) Clinical Outcomes After Teclistamab Failure in Relapsed/Refractory Multiple Myeloma
(PA-036) Effectiveness, Safety and Clinical Use of Teclistamab in Patients with Triple-class-exposed Multiple Myeloma. Data from the Danish ABC-study
(PA-037) Real World Accelerated Step-up Dosing of Teclistamab and Talquetamab in the Outpatient Setting Is Feasible and Associated with Low Incidence of Cytokine Release Syndrome
(PA-038) Optimizing the Use of Chimeric Antigen Receptor T-cell (CART) Therapy for Relapsed/refractory Myeloma
(PA-039) Differential Impact of BCMA (TNFRSF17) Extracellular Domain Mutations on in vitro Potency of Elranatamab versus Teclistamab
(PA-040) Overcoming Resistance in CD44-Overexpressing Myeloma through combination therapy with ATRA, Bortezomib, and NK Cells
(PA-041) Enhanced Persistence and Antitumor Activity of IL-15–Armored Anti-BCMA CAR NK Cells in Myeloma Mouse Model.
(PA-042) Peak Absolute Lymphocyte Count as a Biomarker for CAR T-cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleuecel
(PA-043) Anti-BCMA-CAR-IL15 Natural Killer Cells Prevent Multiple Myeloma Growth in the Bone Marrow but Allow Later Emergence of Extramedullary Disease
(PA-044) Real-World Treatment Patterns Associated With Elranatamab Among Patients With Relapsed/Refractory Multiple Myeloma: The ALTITUDE-2 Study
(PA-045) Elranatamab Fixed Dosing: The Optimal Dosing Strategy for Safety, Efficacy, and Convenience Across Body Weights
(PA-046) Efficacy and Safety of Less Frequent Dosing With Elranatamab (ELRA) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): A US Subgroup Analysis from MagnetisMM-3
(PA-047) Melphalan-Induced Enrichment of TP53-Mutant CHIP as a Risk Factor for Subsequent CAR-T Related Myeloid Neoplasms in Multiple Myeloma
(PA-048) Preclinical Analysis of Ciltacabtagene Autoleucel Combination Strategies with T Cell Bispecifics and Daratumumab to Support Optimization of Clinical Benefit in Myeloma Patients
(PA-049) Linvoseltamab in Patients (pts) with Relapsed/refractory Multiple Myeloma (RRMM) in the LINKER-MM1 Study: Longer Follow-up and Subgroup Analyses
(PA-050) Comparative Efficacy of Linvoseltamab versus Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Triple-class Exposed Relapsed/refractory Multiple Myeloma: A Matching-adjusted Indirect Comparison
(PA-051) Initial Results of a Phase 2 Study to Evaluate Elranatamab (elran) Post-idecabtagene Vicleucel (ide-cel) Consolidation (EPIC) in Patients with Relapsed/refractory Multiple Myeloma (RRMM)
(PA-052) BCMA CAR-T Cells Capable of il-6-neutralization Bifunctionally Reduce Cytokine Release Syndrome and IL-6-driven Myeloma Growth in Preclinical Models
(PA-054) Outcomes of Patients with Multiple Myeloma Post-BCMA Directed Treatment: An Australian Perspective
(PA-055) CAR-Tscm Cells as an Effective Immune Treatment to Multiple Myeloma Patients
(PA-056) CAC-MM-001: Anti-BCMA CAR-T Therapy Followed by Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities
(PA-057) Outcomes of Outpatient Step-up Dosing (SUD) of Teclistamab and Talquetamab in Patients with Relapsed/refractory Multiple Myeloma (RRMM): Findings from a Large Network of Community Practices in the USA
(PA-058) Real-world Safety Outcomes and Healthcare Resource Utilization (HCRU) During Outpatient, Inpatient, and Hybrid Step-up Dosing (SUD) of Teclistamab (Tec) and Talquetamab (Tal): A Chart Review Study
(PA-059) A Phase 2 Study Measuring MRD Negativity after Talquetamab and Teclistamab Consolidation in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC)
(PA-060) Phase 2 Study of Talquetamab (Tal) + Teclistamab (Tec) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Extramedullary Disease (EMD): RedirecTT-1
(PA-061) Updated Comparative Effectiveness of Talquetamab vs Real-World Physician’s Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
(PA-062) Serologic Immunity to Measles, Mumps, and Rubella in Multiple Myeloma Patients Following Cellular Therapy: A Descriptive Analysis
(PA-064) Linvoseltamab (LINVO) + Carfilzomib (CFZ) in Patients (pts) with Relapsed/refractory Multiple Myeloma (RRMM): Initial Results from the LINKER-MM2 Trial
(PA-065) Real-World Outcomes of Equecabtagene Autoleucel, the First Fully Human BCMA-Targeted CAR-T Therapy, in 150 Patients with Multiple Myeloma (MM): A Multicenter Experience from China
(PA-066) Kinetic Characteristics of T Cells in CAR-T Therapy for Multiple Myeloma: A Real-World Analysis
(PA-067) Infections in Patients (PTS) with Multiple Myeloma (MM) Treated with BCMA-directed Car T Cell Therapies and Bispecific Antibodies: Analysis of the FDA Adverse Event Reporting System (FAERS)
(PA-068) Impact of Neighborhood-level Disadvantage, Travel Distance, and Travel Time on Clinical Outcomes of Multiple Myeloma (MM) Patients Treated with Standard of Care (SOC) Idecabtagene Vicleucel (IDE-CEL)
(PA-069) Integrating Real-world Evidence to Augment Crossover Adjustment in KarMMa-3: A Case Study in Relapsed/Refractory Multiple Myeloma
(PA-070) An Evaluation of Overall Survival Between B-cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapies and Bispecific Antibodies for the Treatment of Relapsed/refractory Multiple Myeloma
(PA-071) Real-World Safety and Efficacy of BCMA Bispecific Antibodies in Relapsed and Refractory Light Chain Amyloidosis
(PA-072) Optimizing CAR-T Therapy in Multiple Myeloma: Outpatient Reinfusion of Cesnicabtagene Autoleucel (ARI0002h)
(PA-073) Linvoseltamab (LINVO) in Frail Patients (pts) with Relapsed/refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the LINKER-MM1 Study
(PA-074) Circulating Plasma Cells Evaluation Before and After CAR T-cell Therapy as a Dynamic Factor for Response Assessment
(PA-075) Macrophage Activation Syndrome-Like in Multiple Myeloma Patients Treated with the Academic Bcma-Directed Car-T Ari0002h: Genomic Insights and Clinical Implications
(PA-076) Long-term Follow-Up of a Phase 1 Study of Arlocabtagene Autoleucel (arlo-cel; BMS-986393) in Patients With Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM)
(PA-077) Trial in Progress: QUINTESSENTIAL—A Phase 2 Study of Arlocabtagene Autoleucel (arlo-cel) in Triple- and Quad-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma (RRMM)
(PA-078) Optimizing Post–Chimeric Antigen Receptor (CAR) T-Cell Monitoring: Evidence Across Idecabtagene Vicleucel (ide-cel) Pivotal Clinical Trials and Real-World Experience
(PA-079) Trial in Progress: QUINTESSENTIAL-2—A Phase 3 Study of Arlocabtagene Autoleucel vs Standard of Care in Adult Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Refractory to Lenalidomide
(PA-080) Arlocabtagene autoleucel, a GPRC5D-Targeted CAR T-Cell Therapy for Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1–3 Prior Regimens
(PA-081) Consolidative Use of BCMA CAR-T Therapy in Relapsed/Refractory Myeloma — A Retrospective Evaluation
(PA-082) Real-world Outcomes of Patients with Multiple Myeloma Who Received BCMA-targeted Bispecific Antibodies in British-Columbia
(PA-083) Talquetamab in Brazil: Initial Experience and Outcomes Within an Expanded Access Program
(PA-084) Drivers of Primary Resistance to BCMA-targeted T Cell Redirected Therapies in High Tumor Burden
(PA-085) TRAIL-CD28 Armoring Enhances anti-BCMA CAR-T Cell Function and Overcomes Resistance in Multiple Myeloma
(PA-086) Real-world Healthcare Resource Utilization (HCRU) Following Outpatient (OP) or Inpatient (IP) Administration of Ciltacabtagene Autoleucel (Cilta-cel)
(PA-087) Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Teclistamab
(PA-088) Analysis of Patients With Prior BCMA-Targeted Therapy and Those Achieving CR in REALiTAL: A Multi-Country Observational Study of Talquetamab in RRMM Outside of Clinical Trials
(PA-089) Debulking Chemotherapy Abrogates the Risk of Non-Response in Multiple Myeloma Patients with High Tumor Burden Receiving Teclistamab
(PA-090) Deficiencies in Cellular Immunity Associated with Increased Risk of Infection with Bispecific Antibody Therapy in Multiple Myeloma
(PA-091) Outcomes of Radiation Therapy Integrated with T-cell Engaging Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
(PA-092) Clinicopathological Analysis of Parkinsonism-like Neurotoxicity after BCMA-Directed CAR-T Therapy: An Autopsy Case With Idecabtagene-Vicleucel
(PA-093) Outcomes of CAR-T Cell Therapy in patients with AL Amyloidosis
(PA-094) Early Mortality Associated with Real-World Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma
(PA-095) Efficacy and Safety of CAR-T Therapy in CNS-MM
(PA-096) Abnormal Serum Immunofixation Patterns (ASIP) Are a Common Event Following BCMA CAR-T in Relapsed Refractory Multiple Myeloma and Are Often Preceded by Immunological Events
(PA-097) Prophylactic Dexamethasone (dex) with Outpatient Step-Up Dosing (SUD) of Bispecific Antibodies (BsAb) in Multiple Myeloma (MM) v. Standard of Care (SOC) Inpatient Observation
(PA-098) Excellent Outcomes with BCMA Directed T Cell Redirecting Therapies in t(11,14) Relapsed/ Refractory Multiple Myeloma
(PA-099) High ALC Peak Post Cilta-Cel Infusion Predicts Risk for Delayed Neurological Toxicities
(PA-100) Efficacy of Subsequent T Cell Engagers Following BCMA CAR-T Therapy in Patients with Relapsed/refractory Multiple Myeloma: A Systematic Review and Meta-analysis
(PA-101) Long-Term Follow-Up from MajesTEC-1 China Cohort of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: Efficacy Updates, Infection Profile and Immunoglobulin Usage
(PA-102) Quality-adjusted Survival Analysis of Cilta-cel vs Standard of Care in Lenalidomide-refractory Multiple Myeloma Patients Who Received 1–3 Prior Lines of Therapy: CARTITUDE-4 Trial Population
(PA-103) Value of the Treatment-free Period Following Ciltacabtagene Autoleucel Infusion in Patients with Relapsed/refractory Multiple Myeloma: Preliminary Findings from a Qualitative Interview Study
(PA-104) Splenomegaly Is Associated with High-tumor Burden, Prolonged Cytopenia and Adverse Outcome After BCMA-directed CAR T-cell Therapy
(PA-105) CART–ASCT–CART2 Sandwich Regimen as Frontline Therapy: A Phase II Trial in Patients with Primary Plasma Cell Leukemia
(PA-106) BCMA CAR T-cell Therapy in Newly Diagnosed Transplant-ineligible Multiple Myeloma: An Open Label, Single-arm, Phase 2 Study (CAREMM-001)
(PA-107) Impact of Frailty Tools on Outcomes in Myeloma: MRP and Simplified Index Predict Survival but Differ in Infection Risk Stratification
(PA-108) A Comparison of Chemo-free Strategy with Plerixafor Plus G-CSF versus High-dose Cyclophosphamide Plus G-CSF as First-line PBSC Mobilization in Multiple Myeloma Patients: A Chinese Explorative Study
(PA-517) BCMA CAR-T Therapy with Radiotherapy Bridging and Maintenance Achieves Unprecedented Complete Response in Extramedullary Myeloma
(PA-518) Case Report: BCMA-targeting CAR T-cell Therapy Induces Complete and Durable Remission in Relapsed Extramedullary Plasmablastic Multiple Myeloma
